---
title: "Key facts: Amylyx (AMLX) Files $350M Offering; Target Raised to $55"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296316408.md"
description: "Amylyx (AMLX) filed a $350M common stock offering with a 30-day option for $52.5M more. Proceeds target avexitide pre-commercial work, manufacturing, R&D, and general corporate needs. 3 sourcesHC Wainwright kept a Buy on Amylyx Pharmaceuticals (AMLX) and raised the 1-year price target to $55 from $34, a $21 increase — key for traders tracking upside potential. Dow Jones NewswiresDisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources."
datetime: "2026-08-19T07:14:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296316408.md)
  - [en](https://longbridge.com/en/news/296316408.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296316408.md)
generator: "portal-rs"
---

# Key facts: Amylyx (AMLX) Files $350M Offering; Target Raised to $55

-   Amylyx (AMLX) filed a $350M common stock offering with a 30-day option for $52.5M more. Proceeds target avexitide pre-commercial work, manufacturing, R&D, and general corporate needs. 3 sources
-   HC Wainwright kept a Buy on Amylyx Pharmaceuticals (AMLX) and raised the 1-year price target to $55 from $34, a $21 increase — key for traders tracking upside potential. Dow Jones Newswires

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

### Related Stocks

- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)

## Related News & Research

- [AMLX: Avexitide achieved a 55% reduction in severe hypoglycemic events in PBH, with strong safety data](https://longbridge.com/en/news/296234006.md)
- [AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial](https://longbridge.com/en/news/296265581.md)
- [39,241 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Bought by GSA Capital Partners LLP](https://longbridge.com/en/news/296452266.md)
- [Amylyx Pharmaceuticals Prices 14.09M-Share Public Offering at $35.50; Nets ~$472M](https://longbridge.com/en/news/296538977.md)
- [Amylyx Says Phase 3 Trial of Avexitide For Post-Bariatric Hypoglycemia Met Main Goal](https://longbridge.com/en/news/296218787.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**